TEST BANK FOR ABRAMS'
CLINICAL DRUG THERAPY:
RATIONALES FOR NURSING
PRACTICE 13TH EDITION BY
FRANDSEN AND PENNINGTON ALL
CHAPTERS 1-61 LATEST
Abrams' Clinical Drug Therapy: Rationales for Nursing
Practice — Available Exam Questions
Chapter 1: The Foundation of Pharmacology — Quality and
Safety
1. A woman has been prescribed oral paroxetine for obsessive-compulsive
disorder. The expected effect of this prescription is:
A. A curative effect on her symptoms
B. A systemic effect on her symptoms
C. A local effect on her symptoms
D. A parenteral effect on her symptoms
Rationale: Drugs that produce systemic effects are taken into the body, circulated
through the bloodstream to their sites of action in various body tissues, and eventually
eliminated from the body. Paroxetine will control symptoms but not cure the disorder.
Drugs with local effects (e.g., sunscreen, local anesthetics) act primarily at the site of
application. Paroxetine is not administered parenterally .
,2. A client has been prescribed an antibiotic. The drug is a naturally occurring
substance that has been chemically modified. What is another name for this type
of drug?
A. Synthetic drug
B. Semisynthetic drug
C. Biotechnology drug
D. Prototype drug
Rationale: Semisynthetic drugs (e.g., many antibiotics) are naturally occurring
substances that have been chemically modified. Synthetic drugs are more standardized
in chemical characteristics and produce more consistent effects, with less likelihood of
allergic reactions. Biotechnology drugs involve manipulating DNA and RNA .
3. Morphine is classified under which category?
A. Central nervous system depressant
B. Central nervous system stimulant
C. Anti-inflammatory
D. Antihypertensive
Rationale: Drugs are classified according to their effects on specific body systems,
therapeutic uses, and chemical characteristics. Morphine is classified as a central nervous
system depressant and will produce this effect in clients .
4. A client is given amoxicillin. The generic name of this drug belongs to which
drug group?
A. Selective serotonin reuptake inhibitors
B. Diuretics
C. Penicillins
D. ACE inhibitors
Rationale: The generic name of a drug indicates the drug group (e.g., drugs with
generic names ending in "cillin" are penicillins) .
5. The administration of diphenhydramine is regulated by which U.S. government
agency?
A. Public Health Service
B. Federal Trade Commission
C. Occupational Safety and Health Administration
D. Food and Drug Administration
, Rationale: The Food and Drug Administration (FDA) approves drugs for over-the-
counter availability, including switching drugs from prescription to OTC status .
Chapter 2: Basic Concepts and Processes (Pharmacokinetics)
6. The nurse is reviewing a drug's pharmacokinetics. Which phase describes the
movement of a drug from the site of administration into the blood?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Rationale: Absorption is the process by which a drug moves from the site of
administration into the blood. Distribution is transport in the body. Metabolism
(biotransformation) is the process by which the body changes a drug. Excretion is
elimination from the body.
7. The nurse is caring for a patient receiving a drug with a high first-pass effect.
The nurse expects which route of administration to be most affected?
A. Intravenous
B. Oral
C. Subcutaneous
D. Intramuscular
Rationale: Drugs administered orally are absorbed from the gastrointestinal tract,
transported via the portal circulation to the liver. The liver metabolizes a considerable
portion of the drug before it reaches systemic circulation, reducing bioavailability .
8. A patient is prescribed a highly protein-bound drug. The nurse should monitor
for what?
A. Increased drug effectiveness
B. Decreased drug effectiveness
C. Increased risk of drug interactions
D. Decreased risk of adverse effects
Rationale: Highly protein-bound drugs can be displaced by other drugs that bind to the
same protein sites, increasing the free (active) concentration of the drug and the risk of
toxicity. This can lead to significant drug interactions .
CLINICAL DRUG THERAPY:
RATIONALES FOR NURSING
PRACTICE 13TH EDITION BY
FRANDSEN AND PENNINGTON ALL
CHAPTERS 1-61 LATEST
Abrams' Clinical Drug Therapy: Rationales for Nursing
Practice — Available Exam Questions
Chapter 1: The Foundation of Pharmacology — Quality and
Safety
1. A woman has been prescribed oral paroxetine for obsessive-compulsive
disorder. The expected effect of this prescription is:
A. A curative effect on her symptoms
B. A systemic effect on her symptoms
C. A local effect on her symptoms
D. A parenteral effect on her symptoms
Rationale: Drugs that produce systemic effects are taken into the body, circulated
through the bloodstream to their sites of action in various body tissues, and eventually
eliminated from the body. Paroxetine will control symptoms but not cure the disorder.
Drugs with local effects (e.g., sunscreen, local anesthetics) act primarily at the site of
application. Paroxetine is not administered parenterally .
,2. A client has been prescribed an antibiotic. The drug is a naturally occurring
substance that has been chemically modified. What is another name for this type
of drug?
A. Synthetic drug
B. Semisynthetic drug
C. Biotechnology drug
D. Prototype drug
Rationale: Semisynthetic drugs (e.g., many antibiotics) are naturally occurring
substances that have been chemically modified. Synthetic drugs are more standardized
in chemical characteristics and produce more consistent effects, with less likelihood of
allergic reactions. Biotechnology drugs involve manipulating DNA and RNA .
3. Morphine is classified under which category?
A. Central nervous system depressant
B. Central nervous system stimulant
C. Anti-inflammatory
D. Antihypertensive
Rationale: Drugs are classified according to their effects on specific body systems,
therapeutic uses, and chemical characteristics. Morphine is classified as a central nervous
system depressant and will produce this effect in clients .
4. A client is given amoxicillin. The generic name of this drug belongs to which
drug group?
A. Selective serotonin reuptake inhibitors
B. Diuretics
C. Penicillins
D. ACE inhibitors
Rationale: The generic name of a drug indicates the drug group (e.g., drugs with
generic names ending in "cillin" are penicillins) .
5. The administration of diphenhydramine is regulated by which U.S. government
agency?
A. Public Health Service
B. Federal Trade Commission
C. Occupational Safety and Health Administration
D. Food and Drug Administration
, Rationale: The Food and Drug Administration (FDA) approves drugs for over-the-
counter availability, including switching drugs from prescription to OTC status .
Chapter 2: Basic Concepts and Processes (Pharmacokinetics)
6. The nurse is reviewing a drug's pharmacokinetics. Which phase describes the
movement of a drug from the site of administration into the blood?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Rationale: Absorption is the process by which a drug moves from the site of
administration into the blood. Distribution is transport in the body. Metabolism
(biotransformation) is the process by which the body changes a drug. Excretion is
elimination from the body.
7. The nurse is caring for a patient receiving a drug with a high first-pass effect.
The nurse expects which route of administration to be most affected?
A. Intravenous
B. Oral
C. Subcutaneous
D. Intramuscular
Rationale: Drugs administered orally are absorbed from the gastrointestinal tract,
transported via the portal circulation to the liver. The liver metabolizes a considerable
portion of the drug before it reaches systemic circulation, reducing bioavailability .
8. A patient is prescribed a highly protein-bound drug. The nurse should monitor
for what?
A. Increased drug effectiveness
B. Decreased drug effectiveness
C. Increased risk of drug interactions
D. Decreased risk of adverse effects
Rationale: Highly protein-bound drugs can be displaced by other drugs that bind to the
same protein sites, increasing the free (active) concentration of the drug and the risk of
toxicity. This can lead to significant drug interactions .
